These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases. Righi A; Gambarotti M; Sbaraglia M; Sisto A; Ferrari S; Dei Tos AP; Picci P Hum Pathol; 2016 Dec; 58():15-23. PubMed ID: 27544803 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy. Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431 [TBL] [Abstract][Full Text] [Related]
5. Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma. Matsuda K; Miyoshi H; Hiraoka K; Hamada T; Nakashima K; Shiba N; Ohshima K Clin Orthop Relat Res; 2018 Sep; 476(9):1848-1855. PubMed ID: 30024460 [TBL] [Abstract][Full Text] [Related]
6. Vitronectin significantly influences prognosis in osteosarcoma. Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861 [TBL] [Abstract][Full Text] [Related]
7. P16 protein expression as a useful predictive biomarker for neoadjuvant chemotherapy response in patients with high-grade osteosarcoma: A systematic meta-analysis under guideline of PRISMA. Tang Y; Yang C; Guo Z; Fu Y; Yu X; Liu B; Zhou H; Wang J; Li W; Pang Q Medicine (Baltimore); 2017 May; 96(19):e6714. PubMed ID: 28489748 [TBL] [Abstract][Full Text] [Related]
8. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma. Jeon DG; Song WS; Cho WH; Kong CB; Cho SH Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120 [TBL] [Abstract][Full Text] [Related]
9. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501 [TBL] [Abstract][Full Text] [Related]
10. The β5/focal adhesion kinase/glycogen synthase kinase 3β integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy. Le Guellec S; Moyal EC; Filleron T; Delisle MB; Chevreau C; Rubie H; Castex MP; de Gauzy JS; Bonnevialle P; Gomez-Brouchet A Hum Pathol; 2013 Oct; 44(10):2149-58. PubMed ID: 23845472 [TBL] [Abstract][Full Text] [Related]
11. [Therapy-induced changes in osteosarcoma after neoadjuvant chemotherapy (COSS 86 Therapy Study). Correlation between morphologic findings and clinical follow-up]. Werner M; Fuchs N; Salzer-Kuntschik M; Winkler K; Delling G Pathologe; 1996 Jan; 17(1):35-43. PubMed ID: 8685094 [TBL] [Abstract][Full Text] [Related]
12. A preliminary investigation of Beta-hCG expression in patients with osteosarcoma. Masrouha KZ; Khattab R; Tawil A; Abdallah A; Saghieh S; Haidar R; Abboud M; Khoury NJ J Bone Joint Surg Br; 2012 Mar; 94(3):419-24. PubMed ID: 22371553 [TBL] [Abstract][Full Text] [Related]
13. Correlation between apparent diffusion coefficient and histopathology subtypes of osteosarcoma after neoadjuvant chemotherapy. Wang J; Sun M; Liu D; Hu X; Pui MH; Meng Q; Gao Z Acta Radiol; 2017 Aug; 58(8):971-976. PubMed ID: 27852643 [TBL] [Abstract][Full Text] [Related]
14. Modeling Continuous Prognostic Factors in Survival Analysis: Implications for Tumor Staging and Assessing Chemotherapy Effect in Osteosarcoma. Cates JMM Am J Surg Pathol; 2018 Apr; 42(4):485-491. PubMed ID: 29200101 [TBL] [Abstract][Full Text] [Related]
15. [Value of thallium-201 scintigraphy in assessment of neoadjuvant chemotherapy for osteosarcoma]. Huang ZK; Lou C; Fang XQ Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):769-72. PubMed ID: 20021831 [TBL] [Abstract][Full Text] [Related]
17. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response. Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jung ST; Jeon DG J Orthop Sci; 2009 May; 14(3):292-7. PubMed ID: 19499296 [TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy. Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S Hum Pathol; 1998 Oct; 29(10):1050-5. PubMed ID: 9781640 [TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2. Salas S; Jézéquel P; Campion L; Deville JL; Chibon F; Bartoli C; Gentet JC; Charbonnel C; Gouraud W; Voutsinos-Porche B; Brouchet A; Duffaud F; Figarella-Branger D; Bouvier C Int J Cancer; 2009 Aug; 125(4):851-60. PubMed ID: 19449377 [TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]